GLP-1 hub

Everything you need to think clearly about GLP-1 drugs.

Semaglutide, tirzepatide, retatrutide, orforglipron, CagriSema. Approvals, investigational readouts, side-effect profiles, and what to ask before starting.

The approved and the pipeline.

Semaglutide

FDA approved

a.k.a. Ozempic, Wegovy, Rybelsus

The GLP-1 receptor agonist that rewrote obesity medicine.

Tirzepatide

FDA approved

a.k.a. Mounjaro, Zepbound

Dual GIP/GLP-1 agonist delivering the deepest weight loss in any approved drug to date.

Retatrutide

Investigational

a.k.a. LY-3437943

Triple GIP/GLP-1/glucagon agonist. 28.7% weight loss in Phase 2 trials.

Cagrilintide

Investigational

a.k.a. AM833

Long-acting amylin analog designed to stack with semaglutide.

Orforglipron

Investigational

a.k.a. LY-3502970

Small-molecule oral GLP-1 — no injection, no peptide supply chain.

Head-to-head comparisons.

The questions readers actually ask, answered with outcomes data from Phase 3 trials.

Tirzepatide vs semaglutide→Zepbound vs Wegovy→Ozempic vs Wegovy→CagriSema vs tirzepatide→

Weekly GLP-1 coverage

Get every trial readout, approval, and compounding-pharmacy update.

Free. Weekly. Unsubscribe anytime.